GSK_Annual_Report_2021

Message from the Chairperson Despite the challenges, your company remained resilient and focussed on our strategic priorities. Our endeavour was to improve the quality of human life by helping people do more, feel better and live longer. Dear Shareholders, 2020 was an extraordinary and challenging year for all of us. Despite the challenges, your company remained resilient and focussed on our strategic priorities. Our endeavour was to improve the quality of human life by helping people do more, feel better and live longer. Over the course of the year, our learnings and investments in people and technology gave us an opportunity to enhance access to our focus brands and prepare us for future product launches. Our business continuity measures ensured consistent growth of our focus brands, with Augmentin, Betnovate, Calpol, Ceftum, and Synflorix featuring among the top brands in the Indian Pharmaceuticals Market (IPM). Your company also continued to lead the private market in the vaccines segment with its diversified portfolio to protect children, adolescents and adults. Despite the headwinds caused by COVID-19, the vaccines business bounced back to pre-COVID performance in the last quarter of 2020. Your company launched the tetravalent influenza Northern Hemisphere vaccine ( Fluarix tetra NH 2020-21) in September 2020 and garnered 35% volume share within three months of launch, taking the second position in a market occupied by four brands. Equally, innovation for healthcare impact is at the heart of what we do in India, exemplified by the recent launch of biologic for Severe Eosinophilic Asthma – Nucala . To further enable treatment continuity owing to restrictions and challenges faced by patients due to the pandemic, your company launched “Nucala home administration programme”. This initiative has been a huge saviour for patients during these times. While your company’s patient-centric approach remained unshakeable as ever, we also prioritised those who make the realisation of our purpose possible – our employees – as we continued to support them with various initiatives focussing on their health and wellbeing. During the lockdown, your company focussed on skill enhancement of employees – particularly the field-force – to give them a competitive edge in the ‘new normal’ business context. The pandemic has revealed opportunities to partner with governments and help support the national health goals of India. Your company’s parent organisation, GSK plc, has entered into an in-principle global partnership with Novavax to produce up to 60 million doses of the Covid-19 vaccine. It is also working with Sanofi and Medicago to harness the adjuvant technology in developing Covid-19 vaccines while also collaborating with CureVac to develop mRNA vaccines which have the potential to address multiple Covid-19 variants that are emerging across the world. Your company has shown remarkable agility and resilience throughout the year in unprecedented circumstances. This has included hundreds of colleagues who have continued to work in the Nashik manufacturing site throughout the pandemic to ensure that vital medicines continued to be manufactured so as to reach patients. I want to thank our remarkable workforce and our partners, for without them we would have not succeeded. R.S. Karnad 2 Company Overview GlaxoSmithKline Pharmaceuticals Limited